Carving a new trail in immunology
First Tracks Biotherapeutics is a clinical‑stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases.
Where bold science becomes action
Theresa working in the First Tracks lab
First Tracks Bio is built on a simple but powerful belief: scientific exploration and innovation matter most when they create impact.
Our name reflects the pioneering spirit that drives us. We embrace the courage to go first, the confidence to carve a new trail and the excitement of transforming scientific insight into meaningful impact for all our stakeholders.
Guided by this spirit, we pursue a focused strategy to efficiently advance a high value immunology portfolio that delivers meaningful impact where it’s needed most.
Because patients deserve a future that looks nothing like their past. A future where autoimmune diseases no longer define a life, a family or a dream.
News Releases
Anaptys News
First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) today announced its launch as an independent, publicly traded clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Bio will trade on the Nasdaq Global Select Market, commencing today, under the ticker symbol “TRAX.”